In last trading session, ImmunityBio Inc (NASDAQ:IBRX) saw 3.34 million shares changing hands with its beta currently measuring 0.22. Company’s recent per share price level of $2.69 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $2.37B. That closing price of IBRX’s stock is at a discount of -291.45% from its 52-week high price of $10.53 and is indicating a premium of 15.24% from its 52-week low price of $2.28. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.79 million shares which gives us an average trading volume of 6.44 million if we extend that period to 3-months.
For ImmunityBio Inc (IBRX), analysts’ consensus is at an average recommendation of Sell while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 1 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.14 in the current quarter.
ImmunityBio Inc (NASDAQ:IBRX) trade information
ImmunityBio Inc’s shares saw a change of 5.08% in year-to-date performance and have moved 8.47% in past 5-day. ImmunityBio Inc (NASDAQ:IBRX) showed a performance of -1.82% in past 30-days. Number of shares sold short was 63.18 million shares which calculate 10.24 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 55.17% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -123.05% in reaching the projected high whereas dropping to the targeted low would mean a loss of -123.05% for stock’s current value.
ImmunityBio Inc (IBRX) estimates and forecasts
This year revenue growth is estimated to rise 610.07% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 16.6M for the same. And 3 analysts are in estimates of company making revenue of 22.6M in the next quarter. Company posted 40k and 1.05M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 2.39% during past 5 years.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
Insiders are in possession of 60.87% of company’s total shares while institution are holding 9.59 percent of that, with stock having share float percentage of 24.51%. Investors also watch the number of corporate investors in a company very closely, which is 9.59% institutions for ImmunityBio Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at IBRX for having 13.83 million shares of worth $87.42 million. And as of 2024-06-30, it was holding 2.0135 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 11.42 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.6629 of outstanding shares, having a total worth of $72.19 million.
On the other hand, SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Feb 28, 2025 , the former fund manager was holding 5.84 shares of worth $15.71 million or 0.68% of the total outstanding shares. The later fund manager was in possession of 5.73 shares on Dec 31, 2024 , making its stake of worth around $15.42 million in the company or a holder of 0.67% of company’s stock.
